Status:
COMPLETED
A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children
Lead Sponsor:
U.S. Army Medical Research and Development Command
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Dengue
Eligibility:
All Genders
6-9 years
Phase:
PHASE1
PHASE2
Brief Summary
One year follow-up on immunogenicity and safety of a booster dose of DEN vaccine administered approx. 1 year following the second dose
Detailed Description
The purpose of this study is to find out more about the two doses of dengue vaccine, over a five year period, that the children received in the Dengue-003 study and to study a third dose of dengue tha...
Eligibility Criteria
Inclusion
- Subjects who received two doses of DEN vaccine in the Dengue-003 study
- Subjects whos parents signed an informed consent form were eligible for participation in the five year follow-up study
Exclusion
- None
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01843621
Start Date
February 1 2005
End Date
February 1 2009
Last Update
November 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pediatrics, Phramongkutklao Hospital
Phayathai, Bangkok, Thailand, 10400